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Abstract 
Existing trials had not taken enough consideration of their population representativeness, which can lower the 
effectiveness when the treatment is applied in real-world clinical practice. We analyzed the eligibility criteria of 
Bevacizumab colorectal cancer treatment trials, assessed their a priori generalizability, and examined how it affects 
patient outcomes when applied in real-world clinical settings.  To do so, we extracted patient-level data from a large 
collection of electronic health records (EHRs) from the OneFlorida consortium.  We built a zero-inflated negative 
binomial model using a composite patient-trial generalizability (cPTG) score to predict patients’ clinical outcomes 
(i.e., number of serious adverse events, [SAEs]).  Our study results provide a body of evidence that 1) the cPTG scores 
can predict patient outcomes; and 2) patients who are more similar to the study population in the trials that were used 
to develop the treatment will have a significantly lower possibility to experience serious adverse events. 
Introduction 
Clinical studies (trials) are essential in evidence-based medicine.1  Clinical trials, however, are often conducted under 
idealized and rigorously controlled conditions to improve their internal validity and success rates; but such conditions, 
paradoxically, may compromise their external validity (i.e., trial results’ generalizability to the real-world target 
populations).2  These idealized conditions are sometimes exaggerated and reflected as overly restrictive eligibility 
criteria.2  The generalizability and study population representativeness have long been major concerns.2,3  Certain 
population subgroups, such as older adults,4,5 are often underrepresented due to unjustified exclusion criteria, 
especially in cancer studies6–10.  The underrepresentation of these population subgroups can lead to low trial 
generalizability, and subsequently, reduce treatment effectiveness and increase the likelihood of adverse outcomes in 
these population subgroups when the treatments are moved into real-world clinical practice.  As a consequence, some 
approved drugs have been withdrawn from the market after serious adverse drug reactions were observed on 
population subgroups excluded from the original trials.11  
In clinical trials, the target population represents the patients to whom the results of the 
clinical trials are intended to be applied.  The study population represents the patients 
being sought as defined in the clinical trial eligibility criteria (Figure 1).  To ensure 
patient safety and demonstrate treatment efficacy, eligibility criteria are often restrictive, 
thus representing a constrained subset of the target population.  Further, study samples 
are the enrolled participants of a trial.  Even though study participants are screened based 
on eligibility criteria, due to real-world constraints such as trial awareness, the study 
sample may not adequately represent the study population defined by the eligibility 
criteria.  Further, it is worth noting that the notions of generalizability and population 
representativeness are related but distinct.  Population representativeness measures the 
study population’s coverage of real-world patients, with respect to study traits (e.g., age, 
vitals, and labs), often defined by eligibility criteria.  On the other hand, generalizability 
is the portability of the causal effects of an intervention to real-world settings.  Besides population representativeness, 
other factors also affect studies’ generalizability, such as variation in patients across different clinical settings, 
discrepancies in conditions under which a trial was conducted, and incomplete reporting.12,13  Nevertheless, population 
representativeness of the study population is one of the determining factors for its generalizability. 
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There are two major types of approaches to assessing a study’s population representativeness: 1) the a priori 
generalizability is the representativeness of eligible participants (study population) to the target population; 2) the a 
posteriori generalizability is the representativeness of enrolled participants (study sample) to the target population. 
The a priori generalizability can also be called as the eligibility-driven generalizability, whereas the a posteriori 
generalizability can be called as the sample-driven generalizability.14  However, the a posteriori generalizability is an 
artifact after the fact (i.e., can only be done when a trial is concluded and complete trial data are collected), while the 
a priori generalizability is affected by the trial’s eligibility criteria that are modifiable during the study design phase.   
In 2014, an a priori generalizability score “Generalizability Index for Study Traits” (GIST 1.0; we use 1.0 to 
differentiate these from the GIST 2.0 metrics introduced below) was introduced to quantify the population 
representativeness using eligibility criteria one at a time and real-world patient data.15  The GIST 1.0 score 
characterizes the proportion of patients that would be potentially eligible across trials with the same trait over the 
target population.  GIST 1.0 was validated using a simulated target population.16  As some criteria are correlated, 
GIST was extended to mGIST 1.0 with joint use of multiple eligibility criteria.17  Later, GIST 2.018 was developed to 
consider both 1) the dependencies across multiple criteria in a study, and 2) the significance of individual traits across 
different diseases (e.g., HbA1C is more important in type 2 diabetes than it is in chronic kidney disease).  GIST 2.0 
has two components: sGIST (w.r.t. one criterion) and mGIST (w.r.t. multiple criteria) corresponding to the original 
GIST 1.0 and mGIST 1.0, respectively.  GIST scores are between 0 and 1, where a higher score indicates a greater 
population representativeness.  From now on, we will use sGIST and mGIST to refer to the GIST 2.0 metrics. 
Nevertheless, to be able to rationalize adjustments of eligibility criteria towards ultimately better generalizability early 
on, it is important to identify the relationships among the a priori generalizability and the actual outcomes of the 
interventions/treatments in real-world settings.  Treatment outcomes can be measured in several different ways: 1) 
improvement in clinical outcomes (e.g., better lab results), 2) less adverse events (AEs); and ultimately 3) longer 
survival and better quality-of-life (QoL).  Adverse event is an important measure of treatment safety during clinical 
trials.  Previously, Sen et al. found that GIST 2.0 score was significantly correlated with the number of AEs (i.e., the 
lower the GIST 2.0 score the higher the number of AEs) based on data from 16 sepsis trial results sections in 
ClinicalTrials.gov.14  Nevertheless, their study is limited as it does not provide any evidence on whether the a priori 
generalizability of the trials had any impact on the clinical outcomes (i.e., the number of AEs) when the treatment is 
applied to the target patients in real-world clinical practices.   
On the other hand, the wide adoption of electronic health record (EHR) systems and the proliferation of clinical data 
warehouses with rich real-world patient datasets offer unique opportunities to address these studies.  The U.S. Food 
and Drug Administration (FDA) recently coined the terms real-world evidence (RWE) and real-world data (RWD) as 
“data regarding the usage, or the potential benefits or risks, of a drug derived from sources other than traditional 
clinical trials.”19,20 RWD can come from various sources including EHRs, claims and billing activities as well as 
patient-generated data.  These data will play an increasingly important role in health care and regulatory decisions.   
In this study, we aim to fill this important knowledge gap exploring the hypotheses that 1) the a priori generalizability 
of treatment trials is correlated with the clinical outcomes of the treatment (i.e., the number of AEs) and 2) patients 
who are eligible (i.e., based on the trials’ eligibility criteria and patient characteristics in their EHRs) for the original  
trials used to develop the treatment will have better clinical outcomes than those who are not, when the treatment is 
applied on both eligible/ineligible patients in real-world clinical settings, using RWD—a large collection of linked 
EHRs and claims—from a large clinical data research network.  Our current study focuses on Bevacizumab (under 
the trade name Avastin)—a first of its kind of monoclonal antibody as a tumor-starving (anti-angiogenic) therapy—
approved by the FDA in 2006 for the treatment of metastatic colorectal cancer.21  
Methods 
Data sources 
Bevacizumab (Avastin) clinical trials and trial eligibility criteria.  We obtained free-text eligibility criteria from 
ClinicalTrials.gov—a registry maintained by the National Library of Medicine (NLM) in the United States.  As of 
March 2019, over 299,335 studies across all 50 states in the US as well as in 208 countries are registered on 
ClinicalTrials.gov.  Study information in ClinicalTrials.gov is semi-structured: study descriptors such as study phase, 
intervention type, and locations are stored in structured fields while eligibility criteria are largely free-text.  Through 
ClinicalTrials.gov, we found 57 Bevacizumab trials that met our inclusion criteria: 1) the trial was conducted in the 
US; 2) the primary purpose of the trial is the development of the treatment agent; and 3) excluding post-market 
observational studies (e.g., comparative effectiveness studies, and essentially all Phase IV studies).   
  
Real-world patient data from the OneFlorida.  We obtained individual-level patient data from the OneFlorida Clinical 
Research Consortium (OneFlorida CRC),22 one of the 13 Clinical Data Research Networks (CDRNs) contributing to 
the national Patient-Centered Clinical Research Network (PCORnet) previously funded by the Patient-Centered 
Outcomes Research Institute (PCORI).  PCORnet is now supported by the newly incorporated People Centered 
Research Foundation (PCRF), a nonprofit formed by PCORnet investigators with significant additional infrastructure-
building funds from PCORI.  The OneFlorida data repository integrated various data sources from contributing 
organizations in the OneFlorida CRC currently including 10 healthcare organizations: 1) two academic health centers 
(i.e., University of Florida Health, UFHealth and University of Miami Health System, UHealth), 2) seven healthcare 
systems including Tallahassee Memorial Healthcare (TMH affiliated with Florida State University), Orlando Health 
(ORH), Adventist Health (AH, formerly known as Florida Hospital), Nicklaus Children’s Hospital (NCH, formerly 
known as Miami Children’s Hospital), Bond Community Health (BCH), Capital Health Plan (CHP), and Health 
Choice Network, (HCN), and 3) CommunityHealth IT—a rural health network in Florida.  In addition, OneFlorida 
also obtained claims data from the Florida Medicaid (FLM) program.  As a network, the OneFlorida CRC provides 
care for approximately 48% of Floridians through 4,100 physicians, 914 clinical practices, and 22 hospitals with a 
catchment area covering all 67 Florida counties.23  Most HCOs in OneFlorida contributed EHRs, while CHP and FLM 
contributed claims data.  We linked patients across the different EHRs and claims data sources using a validated 
privacy-preserving record linkage method.24,25  OneFlorida contains only a limited data set under the Health Insurance 
Portability and Accountability Act (HIPAA) and follows the PCORnet Common Data Model (CDM) v4.1 including 
patient demographics, enrollment status, vital signs, conditions, encounters, diagnoses, procedures, prescribing (i.e., 
provider orders for medications), dispensing (i.e., outpatient pharmacy dispensing), and lab results.  The scale of the 
data is ever growing with a collection of longitudinal and robust patient-level records of ~15 million Floridians and 
over 463 million encounters, 917.6 million diagnoses, 1 billion prescribing records, and 1.17 billion procedures as of 
December 2018.  Since our goal is to evaluate the generalizability of Bevacizumab trials as a colorectal cancer 
treatment, we extracted colorectal patients from OneFlorida as the target population using ICD-9/10-CM codes (i.e., 
ICD-9: 153.*, 154.*, 159.0; ICD-10: C18.*, C19.*, C20.*, C26.0).  We identified 39,776 unique colorectal patients 
and extracted their data from OneFlorida.   
 
Figure 2. Overall study design and selection of study populations. 
Overall study design  
There are 3 different populations in our study: 1) population A: OneFlorida colorectal cancer patients who were treated 
with Bevacizumab; 2) population B: patients who were treated with Bevacizumab and eligible for the original trials 
  
that were used to develop the treatment agent (i.e., a subset of population A based on the eligibility criteria of the 
original trials and patient characteristics defined by their EHRs in OneFlorida); and 3) population C: patients who 
were treated with Bevacizumab but NOT eligible for the original trials (i.e., a subset of A).  The selection of and 
relationships among these populations are illustrated in Figure 2.   
We aimed to compare the clinical outcomes (i.e., the number AEs) of population B and population C considering both 
1) the a priori generalizability of the original Bevacizumab trials and 2) whether the patients can be eligible for the 
original trials based on their EHRs.  Our hypothesis is that population B will have better outcomes (i.e., less AEs) 
compared with population C.  To do so, we devised a composite patient-trial generalizability (cPTG) score based on 
GIST that considers both trial generalizability and patient eligibility of the individual trials. 
Our analysis consists of 7 steps: 1) analyzing 
Bevacizumab colorectal cancer treatment trials 
extracted from ClinicalTrials.gov to determine the 
computability of each eligibility criterion and 
constructing queries to extract study traits 
corresponding to each trial eligibility criterion based on 
the OneFlorida data; 2) identifying the different 
populations of interest (i.e., populations B and C as 
described above); 3) calculating each trial’s GIST 
score based on the computable eligibility criteria of 
each trial; 4) determining the eligibility (i.e., a binary 
variable) of each patient for each Bevacizumab trial of 
interest; 5) calculating the composite patient-trial 
generalizability score for each patient; 6) identifying 
each patient’s clinical outcome (i.e., the number of 
serious AEs) of being treated with Bevacizumab; and 
7) comparing the difference in the numbers of serious 
AEs between population B and population C and 
examining the relationships between the cPTG score 
and the number of serious AEs.   
Defining populations of interest and serious adverse events (SAEs) related to using Bevacizumab 
We used International Classification 
of Diseases, Ninth Revision/Tenth 
Revision, Clinical Modification 
(ICD-9/10-CM) codes to identify 
patients who were diagnosed with 
colorectal cancer in the OneFlorida 
data.  Within the colorectal cancer 
patients, we then used the 
Healthcare Common Procedure 
Coding System (HCPCS) codes 
(e.g., C9257, J9035) combined with 
Bevacizumab’s RxNORM (e.g., 
337521) codes to identify the 
administration of Bevacizumab.  To 
identify SAEs in patients treated 
with Bevacizumab, we first reviewed the FDA approved drug label of Bevacizumab using the DailyMed database 
maintained by NLM.  Then for each SAE, we identify the corresponding ICD-9/10-CM codes, as shown in Table 1.  
As shown in Figure 3, to count as a SAE related to Bevacizumab, the SAE diagnosis code has to occur 1) after the 
first Bevacizumab procedure, but 2) within 180 days after the last Bevacizumab procedure.  Note that the first 
Bevacizumab procedure has to occur after the diagnosis of colorectal cancer.  Using these criteria, we counted the 
total number of SAEs for each patient. 
A new composite patient-trial generalizability (cPTG) score based on GIST 
Table 1. ICD-9/10 codes to define serious adverse 
events for Bevacizumab based on its drug label. 
Serious Adverse Event ICD-9-CM ICD-10-CM 
Asymptomatic postprocedural 
ovarian failure 
256.2 E89.40 
Systolic (congestive) heart 
failure 
428.2 I50.2 
Diastolic (congestive) heart 
failure 
428.3 I50.3 
Combined systolic and diastolic 
heart failure 
428.4 I50.4 
Cerebral Hemorrhage 431 I60 
Intracranial Hemorrhage 432.9 I62.9 
Fistula of intestine 569.81 K63.2 
Perforation of intestine 569.83 K63.1 
Gastrointestinal hemorrhage 578 K92.2 
Hematemesis 578.0 K92.0 
Vaginal bleeding 626.8 N93.9 
Epistaxis 784.7 R04.0 
Hemoptysis 786.3 R04.2 
Proteinuria 791.0 R80 
Figure 3. Selection window for serious adverse events related to treating 
colorectal cancer with Bevacizumab. 
  
The original GIST metric quantifies the a priori generalizability of clinical trials with respect to selected quantitative 
eligibility criteria that specify a permissible value range (e.g., HbA1c > 7%), one at a time.15  The GIST score ranges 
from 0 to 1, with 0 being not generalizable and 1 being perfectly generalizable.  In essence, it characterizes the 
proportion of patients potentially eligible across trials.  The extension of GIST, mGIST,17 can quantify the population 
representativeness with joint use of multiple criteria of interest.  Both GIST and mGIST focus on the generalizability 
assessment at the disease domain level (i.e., assessing the generalizability of trials targeting the same disease).  GIST 
2.0 was then introduced as a scalable multivariate metric for quantifying the population representativeness of 
individual clinical trials by explicitly modeling the dependencies among all eligibility criteria.18  The original 
implementation of GIST 2.0 was in Matlab.  We implemented GIST 2.0 in Python and made it available in a public 
Github repository (i.e., https://github.com/Andeeli/GIST.git).  The calculation of sGIST and mGIST is trivial and 
details can be found in the original GIST 2.0 publication.18  One key input is to define the target population (i.e., the 
real-world patient population that the treatment is intended to be applied on).  For our study, we defined patients with 
colorectal cancer and treated with Bevacizumab (i.e., population A) as our target population.  The outputs of GIST 
2.0 are single-trait GIST score (sGIST) for each trait and one multiple-trait GIST score (mGIST) for the trial.   
As the mGIST score is a trial-level variable, we also need to define whether a patient is thought to be eligible of a trial 
based on its eligibility criteria and corresponding patient traits as defined in their EHRs (i.e., based on OneFlorida data 
in our case).  The process is straightforward.  For example, “Platelet count at least 1,500/mm^3” is an inclusion 
criterion in trial NCT00025337.  The lab results for platelet tests are coded using Logical Observation Identifiers 
Names and Codes (LOINC) (i.e., 26515-7, 777-3, and 778-1) in OneFlorida.  Based on these LOINC codes, we queried 
patients’ platelet test results and transformed the measurement unit to mm/^3 if needed.  If a patient’s platelet lab 
result is larger or equal to 1,500/mm^3, we will consider the patient as met this particular inclusion criterion.  We then 
determined the patient’s eligibility (i.e., a binary variable) of the trial, when the patient met all the inclusion criteria 
while did not meet any of the exclusion criteria.  Note that not all eligibility criteria are computable as the needed data 
elements may not exist in their EHRs (e.g., “Fertile patients must use effective contraception”).  We did not use these 
non-computable criteria when determining a patient’s eligibility. 
In order to consider both the patient-level eligibility and trial-level a priori generalizability, we propose a composite 
patient-trial generalizability (cPTG) score.  To calculate cPTG score, we first calculated the mGIST score (ranging 
from 0 to 1) for each trial.  Then, we used patients’ traits data (from OneFlorida) to create an index (i.e., 0 as not 
eligible or 1 as eligible) to indicate whether a patient is eligible for the specific trial or not.  We then took the average 
of the dot product of the vector of mGIST and the vector of patient’s eligibility as follows: 
𝑐𝑃𝑇𝐺𝑖 =  
1
𝐾
∑ 𝑒𝑖𝑗𝑔𝑗
𝐾
𝑗
 
where eij is the eligibility (0 or 1) for patient i of trial j, and gj is the generalizability score (i.e., mGIST) of trial j, for 
each patient i (i.e., i=1,2,…,N) and each trial j (i.e., j=1,2,…,K).  The cPTG score ranges from 0 to 1.  Intuitively, a 
higher cPTG score for a patient means the patient is eligible for more trials in the set of trials of interest and those 
trials have higher a priori generalizability. 
Statistical analysis 
Mean and standard deviation were calculated for continuous variables.  For categorical variables, frequency and 
percentage was calculated.  As more than 80% of the patients in our data have zero adverse events.  We fit a zero-
inflated model to consider the number of SAEs as the outcome and the cPTG score as a predictor.  We also considered 
the following variables as controlling covariates in the model: the number of Bevacizumab procedure, days of follow 
up from latest Bevacizumab procedure, and patient demographics including age, gender, race, and ethnicity.  Since 
the variance of the outcome is much larger than the mean, the data is over-dispersed.  So, we preferred the zero-
inflated negative binomial model to a zero-inflated Poisson regression model.26 
Results 
Cohort characteristics 
We identified 2,531 unique patients who had been diagnosed with colorectal cancer and treated with Bevacizumab 
(out of a total of 39,776 colorectal cancer patients).  Among these patients, 2,034 (80.4%) had no SAE while 497 
(19.6%) had at least one SAE.  The average age of the patient at her/his last Bevacizumab procedure is 59 years old.  
Although male patients are slightly more than female patients, there are more female patients with SAEs. Table 2 
shows the characteristics of our target population.  
  
Table 2. Demographic characteristics and outcomes of the target population in OneFlorida.  
Overall 
(N=2,531) 
# of SAEs = 0 
(N=2,034) 
# of SAE > 0 
(N=497) 
N (or Mean) % (or SD) N (or Mean) % (or SD) N (or Mean) % (or SD) 
Age at last PX (years) 59.09 11.4 59.46 11.4 57.59 11.29 
Gender             
Female 1,206 47.6% 935 46.0% 271 54.5% 
Male 1,325 52.4% 1099 54.0% 226 45.5% 
Race/Ethnicity             
Non-Hispanic White 1,069 42.2% 868 42.7% 201 40.4% 
Non-Hispanic Black 481 19.0% 377 18.5% 104 20.9% 
Hispanic 528 20.9% 407 20.0% 121 24.3% 
Other 17 0.7% 15 0.7% 2 0.4% 
Unknown 436 17.2% 367 18.0% 69 13.9% 
cPTG 0.49 0.20 0.50 0.20 0.45 0.21 
Number of SAEs 0.98 4.08 0 0 4.99 8.04 
Follow up days 103.1 66.97 99.95 67.91 115.96 61.4 
Number of Bevacizumab PXs 10.78 11.63 9.96 10.86 14.17 13.87 
First PX to Last PX in days 263.52 328.17 234.75 296.8 381.21 413.49 
*PX: Procedure; SAE: Serious Adverse Event; SD: Standard Deviation; cPTG: composite patient-trial generalizability 
Analysis of Bevacizumab colorectal cancer trial eligibility criteria 
From the collection of 57 Bevacizumab colorectal trials, we extracted 1,674 eligibility criteria (i.e., 951 inclusion 
criteria and 723 exclusion criteria) from ClinicalTrails.gov.  124 of the 951 (13.04%) inclusion criteria contained 
negations; and 19 of the 723 (2.63%) exclusion criteria contained negations.  On average, each colorectal trial has 26 
(4 to 65) inclusion criteria and 27 (0 to 39) exclusion criteria.  Comparing to our previous study on Hepatitis C Virus 
(HCV) trials27, colorectal cancer trials have significantly more inclusion and exclusion criteria (5.56 inclusion criteria 
and 7.98 exclusion criteria in HCV trials).  We then extracted the core elements of each inclusion/exclusion criterion 
and summarized these 1,674 eligibility criteria into 678 unique criterion patterns.  Many of the inclusion and exclusion 
criterion patterns were fundamentally similar (i.e., querying the same core data elements).  Note that some criteria can 
be decomposed into multiple sub-criteria; we thus considered the smallest units as individual study traits (e.g., “history 
of primary CNS (central nerve system) tumor, or stroke” can be decomposed into “history of primary CNS tumor” and 
“history of stroke”).  Table 3 shows the top 10 most frequent criterion patterns, separated by inclusion vs. exclusion. 
Table 3. Top 10 frequent criterion patterns used by the 57 trials, separated by inclusion vs. exclusion. 
Rank Inclusion Criterion Pattern Study Coverage 
# of Studies (%) 
Exclusion Criterion 
Pattern 
Study Coverage 
# of Studies (%) 
N = 57 N = 57 
1 Aspartate aminotransferase 
(AST) 
32 (56.14%) Unstable angina 36 (63.16%) 
2 Measurable disease 29 (50.88%) Myocardial infarction 34 (59.65%) 
3 Age 29 (50.88%) Radiotherapy 30 (52.63%) 
4 Absolute neutrophil count 29 (50.88%) Congestive heart failure 26 (45.61%) 
5 Platelets 27 (47.36%) Pregnant 22 (38.60%) 
6 Metastatic colorectal cancer 27 (47.36%) Bone fracture 22 (38.60%) 
7 Hemoglobin 25 (43.86%) Significant traumatic injury 22 (38.60%) 
8 Bilirubin 22 (38.60%) Bleeding diathesis 21 (36.84%) 
9 Creatinine 22 (38.60%) Chemotherapy 20 (35.09%) 
10 Alanine transaminase (ALT) 20 (35.09%) Skin ulcers 20 (35.09%) 
However, not all eligibility criteria were computable against our OneFlorida patient database.  We found that 194 
(28.61%) of the 678 unique patterns were not computable.  The main reasons are: (1) the criterion asked for subjective 
information (e.g., patient’s consent or investigator’s judgement of patient’s health status); and (2) the data elements 
needed for the criterion were not presented in the OneFlorida data (e.g., “performance status ecog 0-1” is not captured). 
The composite patient-trial generalizability (cPTG) score 
  
Out of the 57 trials, there are 10 Phase I, 6 Phase I/II, 31 Phase II, and 7 Phase III trials (the other 2 have no phase 
information).  We randomly selected 4 trials out of the 7 Phase III trials to model patient eligibility and trial 
generalizability.  We selected Phase III trials as they are conducted to expand on the safety and effectiveness results 
from Phase I and II trials, to compare the drug to standard therapies, and to evaluate the overall risks and benefits of 
the treatment, right before the treatment can be approved by the FDA and be put on the market.  A Phase III trial 
typically recruits larger groups of people with more relaxed eligibility criteria comparing to Phase I and II trials.   
To calculate cPTG scores, we first calculated the mGIST scores of the 4 trials using population A as the target 
population (i.e., patients who were treated with Bevacizumab for colorectal cancer).  Table 4 lists the total number of 
study traits based on the eligibility criteria (regardless of inclusion or exclusion), the number of computable traits, and 
the mGIST score for each of the 4 trials.  There are 219 unique study traits across the 4 trials, and the top 5 common 
traits are: age, aspartate aminotransferase (AST), bone fracture, pregnancy test, and skin ulcers.   
Table 4. Characteristics of study traits, mGIST scores, and the relationships between eligibility and number of SAEs. 
 
Total # 
of traits 
# of computable 
traits 
mGIST 
Mean # of SAEs Wilcoxon Rank Sums 
Test P value Eligible (SD) Not eligible (SD) 
NCT00025337 46 38 0.547 0.8 (3.0) 1.5 (5.8) <.0001 
NCT00252564 84 64 0.750 1.0 (4.1) 1.4 (4.5) 0.0163 
NCT00096278 88 66 0.584 0.9 (4.1) 1.4 (4.4) 0.0013 
NCT00112918 82 57 0.307 0.5 (2.0) 1.2 (4.6) <.0001 
*SAE: serious adverse event; SD: standard deviation; mGIST: multi- trait Generalizability Index on Study Traits (GIST 2.0). 
We first used Wilcoxon rank sums test to test the difference of the number of SAEs between eligible vs. no eligible 
patients and found the differences are statically significant for all 4 trials (Table 4).  
The relationship between the patient-trial generalizability and clinical outcomes 
The zero-inflated negative binomial model results have two parts, as shown in Table 5.   
Table 5. Zero-inflated negative binomial model for the relationships between cPTG and clinical outcomes. 
Part 1: logistic part for excessive zero (i.e., having no SAE) 
Parameter Estimate Wald 95% Confidence Interval P value 
Age at last Bevacizumab PX 0.03  (-0.01, 0.06)  0.1153 
Female vs Male  -0.78  (-1.4, -0.10) 0.0242 < 0.05 
Race/Ethnicity 
    Hispanic vs NHW -0.55  (-1.37, 0.27) 0.1882 
    NHB vs NHW      -0.35  (-1.12, 0.42) 0.3767 
    Other vs NHW    0.12  (-4.09, 4.33) 0.956 
    Unknown vs NHW  0.53  (-0.22, 1.28) 0.1638 
Follow up day  0.00  (-0.01, 0.00) 0.1882 
Number of Bevacizumab PXs  -0.05  (-0.10, -0.01) 0.0262 < 0.05 
cPTG score  1.30  (-0.48, 3.08) 0.1519 
Part 2: negative binomial part 
Parameter Estimate Wald 95% Confidence Interval P value 
Age at last Bevacizumab PX  -0.010  (-0.028, 0.009) 0.3038 
Female vs Male  -0.225  (-0.586, 0.137)  0.223 
Race/Ethnicity 
    Hispanic vs NHW -0.262  (-0.713, 0.189) 0.2542 
    NHB vs NHW      -0.078  (-0.521, 0.364) 0.729 
    Other vs NHW    0.068  (-2.834, 2.970) 0.9633 
    Unknown vs NHW  0.057  (-0.450, 0.564) 0.8249 
Follow up day 0.003  (-0.001, 0.006) 0.1047 
Number of Bevacizumab PXs  0.024  (0.012, 0.037) 0.0002 < 0.05 
cPTG score  -1.079  (-1.996, -0.162) 0.0211 < 0.05 
Dispersion               5.421  (3.561, 8.253)        
  
The first part is a logistic model, estimating the probability of being an excessive zero (i.e., having no SAE).  Two 
variables—gender and the number of Bevacizumab procedures—are statistically significant at 0.05 level in this part 
of the model.  The odds ratio for female verse male of being an excessive zero is exp(-0.78) = 0.458.  This indicates 
that female has a higher possibility of having SAEs than male while holding other predictors constant.  Further, with 
the number of Bevacizumab procedures increasing by 1, the odds of having no SAE decreases by 0.049 (i.e., 1- exp(-
0.05)=0.049).  This indicates that having more Bevacizumab procedures increases the possibility of having SAEs, 
holding other predictors constant.  Although the cPTG score is not statistically significant in the logistic model, the 
estimate equals to 1.30, meaning the odds of having no SAE increase by exp(1.30*0.1) - 1 = 0.139 for a 0.1 increase 
in the patient-trial generalizability score, holding other variables constant. 
The second part is a negative binomial regression model, estimating the expected number of SAEs.  Two variables—
the number of Bevacizumab procedures and cPTG score—are statistically significant at 0.05 level.  The expected 
number of SAEs increases by exp(0.024) – 1 = 0.0243 for 1 increases in the number of Bevacizumab procedures, 
indicating more Bevacizumab procedures would have more SAEs.  Further, the expected change in the number of 
SAEs decreases by 1 – exp(-1.079*0.1) = 0.102 for 0.1 increase in cPTG.  This indicates that a higher cPTG would 
lead to a smaller number of SAEs, while holding other variables constant.  The dispersion is 5.421 (>1); thus, using a 
binomial model is more appropriate than a Poisson model.26 
Discussion and conclusion 
Our results successfully connect the generalizability to clinical outcomes using RWD.  First, we showed that the 
patients who are eligible for the original trials (that were used to develop the treatment, population B in our case) have 
better treatment outcomes compared with those who are not eligible (i.e., population C) in real-world clinical practice.  
This indicates reduced generalizability of the original trials because of the differences between the characteristics of 
the trial (or trial-eligible) population and ineligible population.  Because of these differences, the original trials may 
have failed to gather sufficient safety and efficacy data on the entire target population, resulting in poorer outcomes 
when the treatment is applied in real-world clinical settings.  Second, we devised a new patient-trial generalizability 
score considering both patient-level eligibility and trial-level a priori generalizability.  A higher cPTG score of a 
patient indicates that the patient can be eligible for more (original) trials (i.e., the patient’s characteristics are more 
similar to those in the trial population) and these trails have a higher a priori generalizability.   
These results have multiple implications.  First, it shows the feasibility of using RWD, especially EHRs, to assess 
patients’ clinical outcomes (e.g., adverse events) and examine various patient characteristics associated with these 
outcomes.  Being able to capture AEs using data collected through routine the standard of care provides us the 
opportunity to create informatics surveillance systems for post-market drug safety monitoring.  Comparing to the 
existing AE reporting systems (e.g., the FDA Adverse Event Reporting System, [FAERS]), EHRs is a much richer 
data source (e.g., lab results and diagnoses of other diseases) that provides a more complete picture of patients’ 
characteristics.  Further, being able to work with data from a large data research network not only gives us a large 
sample size and sufficient statistical power to make robust conclusions but also makes our approaches adaptable to 
other similar networks.  Because of the use of a common data model (CDM), our study can be readily replicated in 
other sites of the PCORnet, which covers more than 100 million patients across the United State.28  Moreover, it is 
also possible to extend our study to other clinical research network initiatives such as the National Center for 
Advancing Translational Sciences (NCATS)’s Clinical and Translational Science Awards Accrual to Clinical Trials 
(CTSA ACT) network and the Observational Health Data Sciences and Informatics (OHDSI) consortium.  Even 
though they are using different CDMs, adapting our approach to a new CDM is rather straightforward. 
Further, our study builds a body of evidence to support the development of an eligibility criteria design tool for 
optimizing study generalizability at the study design phase.  Such an eligibility criteria design tool is much needed 
and will benefit stakeholders of the clinical trial communities.  To the extent that trial participants share the same 
characteristics as the majority of patients, trails should be developed to fit patient profiles seen in real-world clinical 
practice, and thus, facilitate the application of trial results to real-world clinical settings.29  This could be achieved if 
trials had few restrictions on eligibility, allowing more representative patients to participate.  A significant proportion 
of real world patients are unable to participate in clinical trials due to stringent exclusion criteria, but many still 
received treatment outside of clinical trials and benefited from therapy.30  A recent special issue on eligibility criteria 
in the Journal of Clinical Oncology—a leading clinical oncology research journal—calls for “broadening eligibility 
criteria to make clinical trials more representative.”31  As a response, the National Cancer Institute (NCI) has revised 
its clinical trial protocols to expand access for previously excluded patients in an effort to ensure that study participants 
are more reflective of real-world populations.32  Our study provides initial data evidence that 1) a priori 
  
generalizability is qualifiable and 2) combined with patient eligibility, the cPTG score can predict clinical outcomes 
in real-world patients.  This eventually could lead to metrics that rationalize the design (or relaxation) of eligibility 
criteria. 
Last, our study also leads to opportunities to develop a computable eligibility criteria framework for EHR-based cohort 
identification to facilitate trial recruitment.  One can imagine a tool that a trial investigator could not only identify 
patients who are eligible to the trial of interest based on their EHRs, but also be able to estimate the impact of recruiting 
a particular patient on the trial’s generalizability and possible clinical outcomes on similar patients.   
Our study is not without limitations.  The process of analyzing and decomposing existing eligibility criteria into 
computable eligibility criteria against EHRs is both time- and labor-intensive.  Exploring advanced natural language 
processing tools tailored for analyzing eligibility criteria might be beneficial.  Nevertheless, to tease out the subtle 
ambiguities in free-text eligibility criteria, human judgments are always needed.  Moreover, many eligibility criteria 
cannot be accurately translated into database queries (e.g., “At least 10 days since prior aspirin dose of more than 325 
mg/day”).  We took a simplistic approach and did not consider these temporal constraints, which may lead to a small 
number of inaccurate identifications of patient eligibility.  Further, some criteria (e.g., lab results) may be matched to 
multiple observations (e.g., blood pressure) that vary from time to time.  We made an assumption that the patient will 
meet the criterion as long as if any one of the observations fell into the permissible value range.   
In sum, our results are significant.  Our ultimate goal is to provide an easy-to-use and more efficient computable 
eligibility criteria construction platform for investigators to identify eligible patients based on their existing EHRs 
while maximizing the trial’s a priori generalizability. 
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